Advances of using antibody against B cell activating factor for treatment of autoimmune diseases.
- Author:
Rongrong LIN
1
;
Yulei CHEN
1
;
Tengchuan JIN
2
;
Minjie CAO
1
Author Information
- Publication Type:Review
- Keywords: B cell activating factor; B-cell maturation antigen; BAFF receptor; autoimmune diseases; calcium modulator; cyclophilin ligand interactor; transmembrane activator
- MeSH: Autoimmune Diseases/drug therapy*; B-Cell Activating Factor/therapeutic use*; B-Lymphocytes; Humans; Interleukin-4; Lupus Erythematosus, Systemic/drug therapy*
- From: Chinese Journal of Biotechnology 2022;38(3):903-914
- CountryChina
- Language:Chinese
- Abstract: In recent decades, the treatment of autoimmune diseases has moved from the use of hormones and conventional immunosuppressive drugs to biological agents. B cell proliferation and maturation play crucial roles in the development of autoimmune diseases. The tumor necrosis factor superfamily ligand B cell activating factor (BAFF) and its receptor mediate B cell survival through regulating signaling pathways. Therefore, BAFF and its receptors are important therapeutic targets for the treatment of autoimmune diseases. This review describes the mechanism of BAFF and its receptor in the human body system and introduces the latest views on how over-activation of BAFF pathway promotes the development of autoimmune diseases including systemic lupus erythematosus, Sjogren's syndrome, and rheumatoid arthritis. In connection to the treatment of the above three diseases, this review discusses the clinical trials and application status of three BAFF-targeting antibody drugs, including Belimumab, Tabalumab and Atacicept. Finally, this review proposes new strategies that targeting the BAFF pathway to provide a new treatment for autoimmune diseases.
